Eckert&Ziegler acquires the Analytic Instrumentation and Radiochemistry Equipment Business from American market leader Bioscan, Inc.
(firmenpresse) - Eckert&Ziegler Strahlen- und Medizintechnik AG / Key word(s):
Research/Technology/
Eckert&Ziegler acquires the Analytic Instrumentation and
Radiochemistry Equipment Business from American market leader Bioscan,
Inc.
DGAP-Media / 05.07.2011 / 16:05
Press Release
Eckert&Ziegler acquires the Analytic Instrumentation and Radiochemistry
Equipment Business from American market leader Bioscan, Inc.
Berlin, Germany, 05 July 2011. Eckert&Ziegler Strahlen- und
Medizintechnik AG (ISIN DE0005659700), specialists in radioactive
pharmaceuticals and their production technology, has entered into an
agreement with Bioscan, Inc., located in Washington, D.C., to acquire its
radiopharmaceutical equipment business. The transaction involves both
analytical instruments used in quality assurance of radioactive
pharmaceuticals and automated radiopharmaceutical synthesis units. Such
equipment is used worldwide in the production of radiolabeled molecular
imaging agents used in nuclear medicine.
Eckert&Ziegler Radiopharma Board member, Dr. AndréHeß, explained: 'The
products we have acquired ideally enhance our developing equipment business
and ensure we can offer our customers system solutions for the production
and quality assurance of radiopharmaceuticals. By such an investment we are
broadening our commitment to the North American market.'
'Bioscan has been a leading player in radioanalytic and radiochemistry
instrumentation for more than thirty years. Over the past five years, the
company has increasingly focused on its fast-growing molecular imaging
business', commented Alex Kleinman, Vice President of Marketing and
Business Development for Bioscan. 'Today's transaction will enable Bioscan
to increase investment in its rapidly expanding preclinical imaging product
line. We are pleased to be able to entrust our radiopharmaceutical
equipment business and the thousands of customers that use Bioscan
radioanalytic and radiochemistry instruments every day to a market leader
like Eckert&Ziegler.'
Radiopharmaceuticals are used in so-called positron emission tomography
(PET) to ensure swift and accurate identification of cancerous tissue and
neurodegenerative disease. A large number of radiopharmaceuticals are
currently in the development pipeline and consequently the associated
equipment market continues to grow. In addition to its radiopharmaceutical
synthesis equipment business, Eckert&Ziegler has several Fluorine-18 PET
radiopharmaceutical production locations in Germany and also supplies
research institutes worldwide with its Gallium-68 (PET) radio nuclide
generators for nuclear imaging In addition to these radio-diagnostic
products Eckert&Ziegler also markets the EMEA approved product Yttriga,
an Yttrium-90 precursor for numerous radiotherapeutic products.
About Eckert&Ziegler: Eckert&Ziegler Strahlen- und Medizintechnik AG is
an isotope technology company which operates worldwide and is the holding
company for a host of specialized subsidiaries engaged in the processing of
radioisotopes as well as the development, production and the sales of
isotope technical components, medical technical devices and related
products. The group of companies has 550 employees worldwide and is among
the largest providers of radioactive components for radiation therapy and
nuclear medicine. For more information about Eckert&Ziegler please visit
www.ezag.com.
About Bioscan: Bioscan is a leading supplier of preclinical
nano-tomographic molecular imaging systems that enable breakthroughs in the
discovery, validation and development of novel therapeutics. Preclinical
imaging uses molecular biomarkers in animals to conduct in vivo studies
that generate more relevant and consistent biological data while reducing
research cost and complexity. The company's cutting-edge SPECT, PET,
Optical and X-Ray CT imaging tools are used by more than 100 academic
institutions, government research organizations, pharmaceutical and
biotechnology companies to improve their disease, drug discovery and
development research. The unique imaging acuity enabled by Bioscan's
patented technologies makes it possible to translate research protocols and
results directly from small animal models of human diseases to human
clinical trials, driving increased speed to market for drugs. For more
information about Bioscan please visit www.bioscan.com.
If you have any questions please contact:
Eckert&Ziegler AG, Karolin Riehle, Investor Relations, Robert-Rössle-Str.
10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle(at)ezag.de, www.ezag.de
Bioscan, Inc., Alex Kleinman, Marketing, 4590 MacArthur Blvd. NW,
Washington DC 20007
Tel.: +1-202-338-0974, akleinman(at)bioscan.com, www.bioscan.com
End of Media Release
---------------------------------------------------------------------
05.07.2011 Dissemination of a Press Release, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Eckert&Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Deutschland
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle(at)ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, Düsseldorf, Hamburg, München
End of News DGAP-Media
---------------------------------------------------------------------
130938 05.07.2011
Datum: 05.07.2011 - 16:05 Uhr
Sprache: Deutsch
News-ID 34541
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 238 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Eckert&Ziegler acquires the Analytic Instrumentation and Radiochemistry Equipment Business from American market leader Bioscan, Inc."
steht unter der journalistisch-redaktionellen Verantwortung von
Eckert&Ziegler Strahlen- und Medizintechnik AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
